Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2011, Pages

  Abdel Latif, Mohamed E ^a,b   Osborn, David A ^c  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLARA CELL PROTEIN; CYTOKINE; PLACEBO; RECOMBINANT CLARA CELL PROTEIN 10; RECOMBINANT PROTEIN; SECRETORY PROTEIN; SURFACTANT; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CLARA CELL SECRETORY PROTEIN; LUNG SURFACTANT; UTEROGLOBIN;

ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; CELL COUNT; DRUG TOLERABILITY; HUMAN; INFANT; INFANT DISEASE; INFANT MORTALITY; LEUKOMALACIA; META ANALYSIS; MORBIDITY; MULTICENTER STUDY (TOPIC); NECROTIZING ENTEROCOLITIS; NEUTROPHIL; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; SYSTEMATIC REVIEW; TRACHEAL ASPIRATION PROCEDURE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PILOT STUDY; TRACHEA;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PILOT PROJECTS; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TRACHEA; UTEROGLOBIN;

EID: 79959492324     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008308.pub2     Document Type: Review

References (48)

1. Levine CR, Gewolb IH, Allen K, Welch R, Melby JM, Pilon A, et al. Safety, Pharmacokinetics and Anti-Inflammatory Activity of rhCC10 in Premature Infants with Respiratory Distress Syndrome (RDS) (Abstract). PAS Annual Meeting. 2003. 2695195
2. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatric Research 2005;58(1):15-21. 2695196
3. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, et al. Statement on the care of the child with chronic lung disease of infancy and childhood. American Journal of Respiratory and Critical Care Medicine 2003;168(3):356-96.
4. Bancalari E, del Moral T. Bronchopulmonary dysplasia and surfactant. Biology of the Neonate 2001;80(Supp 1):7-13.
5. Bardin C, Zelkowitz P, Papageorgiou A. Outcome of small-for-gestational age and appropriate-for-gestational age infants born before 27 weeks of gestation. Pediatrics 1997;100(2):E4.
6. Chandra S, Davis JM, Drexler S, Kowalewska J, Chester D, Koo HC. Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury. Pediatric Research 2003;54(4):509-15.
7. Chye JK, Gray PH. Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study. Journal of Paediatrics and Child Health 1995;31(2):105-11.
8. Clark RH, Slutsky AS, Gerstmann DR. Lung protective strategies of ventilation in the neonate: what are they?. Pediatrics 2000;105(1 Pt 1):112-4.
9. Coalson JJ, Winter VT, Siler-Khodr T, Yoder BA. Neonatal chronic lung disease in extremely immature baboons. American Journal of Respiratory and Critical Care Medicine 1999;160(4):1333-6.
10. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003935.pub2]
11. Dierynck I, Bernard A, Roels H, De Ley M. The human Clara cell protein: biochemical and biological characterisation of a natural immunosuppressor. Multiple Sclerosis 1996;1(6):385-7.
12. Doyle LW, Victorian Infant Collaborative Study Group. Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991-1992. Pediatric Pulmonology 2006;41(6):570-6.
13. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58:579-88.
14. Hannaford K, Todd DA, Jeffery H, John E, Byth K, Gilbert G. Role of Ureaplasma urealyticum in lung disease of prematurity. Archives of Disease in Childhood Fetal and Neonatal Edition 1999;81(3):F162-7.
15. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
16. Hughes CA, OGorman LA, Shyr Y, Schork MA, Bozynski ME, McCormick MC. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. Journal of Developmental and Behavioral Pediatrics 1999;20(1):1-8.
17. Johnston CJ, Mango GW, Finkelstein JN, Stripp BR. Altered pulmonary response to hyperoxia in Clara cell secretory protein deficient mice. American Journal of Respiratory Cell and Molecular Biology 1997;17(2):147-55.
18. Kakkera DK, Siddiq MM, Parton LA. Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia. Biology of the Neonate 2005;87(2):82-90.
19. Kilbride HW, Gelatt MC, Sabath RJ. Pulmonary function and exercise capacity for ELBW survivors in preadolescence: effect of neonatal chronic lung disease. Journal of Pediatrics 2003;143(4):488-93.
20. Korhonen P, Koivisto AM, Ikonen S, Laippala P, Tammela O. Very low birthweight, bronchopulmonary dysplasia and health in early childhood. Acta Paediatrica 1999;88(12):1385-91.
21. Kotecha S, Mildner RJ, Prince LR, Vyas JR, Currie AE, Lawson RA, et al. The role of neutrophil apoptosis in the resolution of acute lung injury in newborn infants. Thorax 2003;58(11):961-7.
22. Lassus P, Nevalainen TJ, Eskola JU, Andersson S. Clara-cell secretory protein in preterm infants' tracheal aspirates correlates with maturity and increases in infection. Pediatric Pulmonology 2000;30(6):466-9.
23. Loughran-Fowlds A, Oei J, Wang H, Xu H, Wimalasundera N, Egan C, et al. The influence of gestation and mechanical ventilation on serum Clara cell secretory protein (CC10) concentrations in ventilated and nonventilated newborn infants. Pediatric Research 2006;60(1):103-8.
24. Majnemer A, Riley P, Shevell M, Birnbaum R, Greenstone H, Coates AL. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Developmental Medicine and Child Neurology 2000;42(1):53-60.
25. Mango GW, Johnston CJ, Reynolds SD, Finkelstein JN, Plopper CG, Stripp BR. Clara cell secretory protein deficiency increases oxidant stress response in conducting airways. American Journal of Physiology 1998;275(2 Pt 1):L348-56.
26. Mantile G, Fuchs C, Cordella-Miele E, Peri A, Mukherjee AB, Miele L. Stable, long-term bacterial production of soluble, dimeric, disulfide-bonded protein pharmaceuticals without antibiotic selection. Biotechnology Progress 2000;16(1):17-25.
27. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, et al. Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Journal of Clinical Investigation 1983;72(2):656-66.
28. Oei J, Lui K, Wang H, Henry R. Decreased interleukin-10 in tracheal aspirates from preterm infants developing chronic lung disease. Acta Paediatrica 2002;91(11):1194-9.
29. Oei J, Lui K, Wang H, Henry R. Decreased neutrophil apoptosis in tracheal fluids of preterm infants at risk of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 2003;88(3):F245-9.
30. Ogden BE, Murphy SA, Saunders GC, Pathak D, Johnson JD. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. American Review of Respiratory Disease 1984;130(5):817-21.
31. Peri A, Cordella-Miele E, Miele L, Mukherjee AB. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. Journal of Clinical Investigation 1993;92(5):2099-109.
32. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001;164(1):155-61.
33. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
34. Roberts D, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2]
35. Shashikant BN, Miller TL, Welch RW, Pilon A, Shaffer TH, Wolfson MR. Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. Journal of Applied Physiology 2005;99(6):2204-11.
36. Skidmore MD, Rivers A, Hack M. Increased risk of cerebral palsy among very low-birthweight infants with chronic lung disease. Developmental Medicine and Child Neurology 1990;32(4):325-32.
37. Soll R. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD001079]
38. Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001456]
39. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD000510]
40. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD000511]
41. Soll R, Özek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000141.pub2]
42. Stevens TP, Blennow M, Myers EW, Soll R. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003063.pub3]
43. Su BH, Chiu HY, Lin TW, Lin HC. Interleukin-8 in bronchoalveolar lavage fluid of premature infants at risk of chronic lung disease. Journal of the Formosan Medical Association 2005;104(4):244-8.
44. Thomas W, Speer CP. Prevention and therapy of bronchopulmonary dysplasia - Evidence and clinical practice. Chinese Journal of Contemporary Pediatrics 2007;9(3):264-75.
45. Wang H, Oei J, Lui K, Henry R. Interleukin-16 in tracheal aspirate fluids of newborn infants. Early Human Development 2002;67(1):79-86.
46. Warner BB, Stuart LA, Papes RA, Wispe JR. Functional and pathological effects of prolonged hyperoxia in neonatal mice. American Journal of Physiology 1998;275(1 Pt 1):L110-7.
47. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97(2):210-5.
48. Wolfson MR, Funanage VL, Kirwin SM, Pilon AL, Shashikant BN, Miller TL, et al. Recombinant human Clara cell secretory protein treatment increases lung mRNA expression of surfactant proteins and vascular endothelial growth factor in a premature lamb model of respiratory distress syndrome. American Journal of Perinatology 2008;25(10):637-45.